Search results for "Adjuvant"
showing 3 items of 733 documents
Adherence to oral hormonal anticancer agents in breast cancer.
2022
There is an increasing trend towards using oral antitumoral agents in oncological patients. Compared to parenteral therapy, oral treatment offers convenience for both the patient and the healthcare system, with similar efficacy. However, the benefit deriving from oral drugs will be obtained only if patients adhere strictly to the treatment. Medical oncologists must therefore seek to optimize patient adherence. Breast cancer patients, particularly, are often treated with oral hormonal anticancer agents. In this review, we summarized evidence about adherence of breast cancer patients to oral hormonal anticancer agents and the consequences of poor compliance, the barriers to oral treatment an…
Gremošanas sistēmas akūtās blaknes onkoloģiskiem pacientiem, saņemot neoadjuvanto mērķterapiju
2020
Bakalaura darba tēma ir “Gremošanas sistēmas akūtas blaknes onkoloģiskiem pacientiem, saņemot neoadjuvantu terapiju”. Bakalaura darba mērķis ir novērtēt akūtas gremošanas sistēmas blaknes onkoloģiskiem pacientiem saņemot tikai staru terapiju vai kombinētu neoadjuvantu mēķterapiju ar taisnās zarnas un tūpļa kanāla audzējiem, balstoties uz RTOG skalas. Bakalaura darbs sastāv no teorijas daļas un pētījuma daļas. Darba apjoms ir 43 lpp. Bakalaura darbā izvirzīta hipotēze ir agrīnas staru terapijas blaknes attīstīsies agrāk un būs smagākas pacientiem, kuri vienlaicīgi saņem staru terapiju un ķīmijterapiju. Pētījuma daļā tika pielietota kvalitatīvi prospektīva pētījuma metode, ar kuras palīdzību …
Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled…
2013
Obesity is an unfavorable prognostic factor in breast cancer (BC) patients regardless of menopausal status and treatment received. However, the association between obesity and survival outcome by pathological subtype requires further clarification. METHODS: We performed a retrospective analysis including 5,683 operable BC patients enrolled in four randomized clinical trials (GEICAM/9906, GEICAM/9805, GEICAM/2003-02, and BCIRG 001) evaluating anthracyclines and taxanes as adjuvant treatments. Our primary aim was to assess the prognostic effect of body mass index (BMI) on disease recurrence, breast cancer mortality (BCM), and overall mortality (OM). A secondary aim was to detect differences o…